



PHARMACEUTICAL 2021













UroGen Pharma Ltd. Rank 251 of 402

The relative strengths and weaknesses of UroGen Pharma Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UroGen Pharma Ltd. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 28% points. The greatest weakness of UroGen Pharma Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 50%, being 3.1% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	115,619
Cost of Goods Sold	1,009
Intangible Assets	0
Liabilities, Current	21,436
Liabilities, Non-Current	1,497
Other Assets	4,340
Other Compr. Net Income	-5.0
Other Expenses	3,374
Other Liabilities	2,717
Other Net Income	1,629
Other Revenues	11,799
Property and Equipment	2,046
Research and Development	47,310
Selling, General and Administrative Expense	90,219

Output Variable	Value in 1000 USD
Assets	122,005
Liabilities	25,650
Expenses	141,912
Revenues	11,799
Stockholders Equity	96,355
Net Income	-128,484
Comprehensive Net Income	-128,486
Economic Capital Ratio	50%

